| "These data suggest that, in dry eyes, treatment with unpreserved artificial tears may lead to an objective improvement in corneal surface disease." | ( Göbbels, M; Spitznas, M, 1992) |
| "We describe a case of dry eye associated with Waldenström's macroglobulinemia that responded poorly to substitutive topical treatment but improved spectacularly in response to systemic chemotherapy." | ( Cordido, M; Fernández-Lago, C; Fernández-Vigo, J; López-Nieto, C, 1995) |
| "59 patients with 'dry eye condition' of various etiology were enrolled in an open multicentre study and treated 8 weeks with a new preservative-free tear substitute." | ( Feuerhake, C; Joost, P; Mayer, H; Sander, U, 1994) |
| "The treatment of dry eyes with artificial tears often fails." | ( Heiligenhaus, A; Kemper, D; Koch, JM; Kruse, FE; Waubke, TN, 1994) |
| "We are now entering a new era in dry eye treatment with the introduction of the first agent that can reverse the basic events of dry eye surface disease." | ( Gilbard, JP, 1996) |
| "Patients with severe dry eye, such as in SS, are good candidates for this treatment." | ( Shinozaki, N; Toda, I; Tsubota, K, 1996) |
| "The observed decrease suggests that dry eye disease involves immune-mediated inflammatory processes that may be decreased by treatment with topical ophthalmic cyclosporine." | ( Feuer, WJ; Ji, Z; Pflugfelder, SC; Reis, BL; Stern, M; Turner, K, 2000) |
| "Treatment of dry eye syndrome with topical cyclosporine significantly reduced the numbers of activated lymphocytes within the conjunctiva." | ( Gipson, IK; Kunert, KS; Smith, JA; Stern, ME; Tisdale, AS, 2000) |
| "We present two cases of severe dry eye in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (SCT) who were successfully treated by the systemic administration of FK506 and corticosteroids." | ( Kuwana, M; Mashima, Y; Mori, T; Nakajima, T; Ogawa, Y; Oguchi, Y; Okamoto, S; Tsubota, K; Watanabe, R; Yamada, M, 2001) |
| "Treatment of dry eye syndrome for 6 months with topical CsA resulted in an increase in goblet cell numbers in patients with NSS-KCS and SS-KCS and a decrease in epithelial turnover in those with NSS-KCS." | ( Gipson, IK; Kunert, KS; Tisdale, AS, 2002) |
| "Until recently, all treatments for dry eye have been palliative." | ( Hirsch, JD, 2003) |
| "Subjects with dry eye (n=527) were evaluated in a randomized, double-masked, parallel-group trial comparing 24 weeks of treatment with 2 concentrations of diquafosol (1% and 2%) versus placebo instilled 4 times daily." | ( Bokosky, JE; Davitt, WF; Kellerman, DJ; LaVange, LM; Mills-Wilson, MC; Nichols, KK; Schaberg, AE; Tauber, J; Yerxa, BR, 2004) |
| "Symptoms of dry eye were mild and reversible; however, abnormalities in tear dynamics and the ocular surface persisted even 6 months after discontinuation of treatment." | ( Chang, TT; Huang, FC; Lin, SC; Shih, MH; Tseng, SH, 2005) |
| "This rat dry eye model, established by repeated JB treatment in desiccating conditions, induced abnormal tear dynamics and superficial punctate keratopathy similar to that in humans." | ( Imagawa, T; Nakamura, S; Nakashima, H; Shibuya, M; Tsubota, K; Uehara, M, 2005) |
| "Therapy of dry eye is usually based upon topical administration of tear substitutes; estrogen or androgen-based eye drops represents a promising innovative treatment based upon important scientific rationale." | ( Campos, EC; Versura, P, 2005) |
| "It provides an alternative choice for dry eye treatment." | ( Chang, YH; Li, WC; Lin, HJ, 2005) |
| "Therapy of chronic dry eye disease with cyclosporine 0." | ( Barber, LD; Foulks, GN; Pflugfelder, SC; Tauber, J, 2005) |
| "Experimental dry eye (EDE) was created in C57BL6 mice, with or without or topical treatment consisting of 1% methylprednisolone, 0." | ( Corrales, RM; De Paiva, CS; Farley, WJ; Li, DQ; Pflugfelder, SC; Stern, ME; Villarreal, AL, 2006) |
| "To report a patient with dry eye after bilateral photorefractive keratectomy (PRK) with mitomycin C treatment in one eye." | ( Diakonis, VF; Ginis, H; Kymionis, GD; Pallikaris, I; Tsiklis, NS, 2006) |
| "The patient developed dry eye symptoms and superficial punctuate keratopathy in the eye treated with mitomycin C." | ( Diakonis, VF; Ginis, H; Kymionis, GD; Pallikaris, I; Tsiklis, NS, 2006) |
| "Current diagnostic tests used in dry eye disease are often neither sensitive nor reproducible, making it difficult to accurately diagnose and determine end points for clinical trials, or evaluate the usefulness of different medications in the treatment of dry eye disease." | ( Asbell, PA; Fahim, MM; Fan, VC; Haji, S; Koonapareddy, CV, 2006) |
| "Patients with dry eye disease demonstrated an increased corneal permeability and a slower rate of elimination to topically administered fluorescein when measured by the fluorophotometer." | ( Asbell, PA; Fahim, MM; Fan, VC; Haji, S; Koonapareddy, CV, 2006) |
| "Experimental dry eye (EDE) was created in C57BL/6 mice, without or with topical therapy, 1% methylprednisolone, 0." | ( Corrales, RM; De Paiva, CS; Farley, W; Li, DQ; Pflugfelder, SC; Stern, ME; Villarreal, AL, 2006) |
| "A total of 10 patients with dry eye due to LTD were treated as follows: one drop of hypotonic 0." | ( Kasetsuwan, N; Prabhasawat, P; Tesavibul, N, 2007) |
| "Eight patients who had had chronic dry eye disease for 3 to 20 years were treated with topical cyclosporine for 6 to 72 months, and then remained free of symptoms or signs of disease for at least 1 year (range, 16-29 months; mean, 21 months) after stopping treatment." | ( Perry, HD; Wilson, SE, 2007) |
| "The average score for the dry eye group was significantly increased compared with that for the nontreatment group at all time points throughout the experiment." | ( Hisamura, R; Imagawa, T; Masuda, N; Nakamura, S; Nakashima, H; Shibuya, M; Tsubota, K; Uehara, M, 2007) |
| "Patients with dry eye (N = 30) seen in a university-affiliated private practice were randomized to 1 of 3 treatments: cyclosporine 0." | ( Brazzo, BG; Carniglia, PE; Roberts, CW, 2007) |
| "All 3 regimens effectively treated dry eye." | ( Brazzo, BG; Carniglia, PE; Roberts, CW, 2007) |
| "Anti-inflammatory treatment of dry eye syndrome may include short-term corticosteroids, cyclosporine A emulsion, oral tetracycline therapy, oral omega-3 fatty acid supplements, and autologous serum eye drops." | ( Gierek-Ciaciura, S; Mrukwa-Kominek, E; Rogowska-Godela, A, 2007) |
| "36 patients with moderate to severe dry eye (5 mm/5 min or less with Schirmer's test or tear break up time (BUT) less than 6 seconds), were treated with topical application of CS-HA on one eye and CsA on the other 4 times a day for 6-8 weeks." | ( Kim, MK; Lee, HJ; Lee, JH; Moon, JW; Shin, KC; Wee, WR, 2007) |
| "Variability in the presentation of dry eye can hinder the observation of treatment effects." | ( Kim, T; Mah, FS; O'Brien, T; Torkildsen, G, 2008) |
| "Patients with dry eye disease (N = 6) defined by an Ocular Surface Disease Index symptom score >or=25, Schirmer test 1 <10 mm, and corneal fluorescein and conjunctival lissamine green staining scores >or=3 were treated with artificial tears (Refresh Plus; Allergan, Irvine, CA) 4 times a day for 4 weeks, followed by 0." | ( De Paiva, CS; Pflugfelder, SC; Stern, ME; Villarreal, AL, 2008) |
| "On treating dry eye model with nimesulide 0." | ( El-Gohary, AA; El-Hossary, GG; El-Shazly, AH; El-Shazly, LH, 2008) |
| "Subjective and objective dry eye assessment was performed for the post-treatment control of lacrimal gland function." | ( Aebersold, D; Curschmann, J; Ghadjar, P; Goldblum, D; Greiner, R, 2008) |
| "A total of 150 patients with defined dry eye disease participated (50 in each treatment group)." | ( Choi, JS; Joo, CK; Kim, EC, 2009) |
| "The understanding of dry eye disease in both its clinical expression and underlying etiopathology has expanded over the past 10 years with implications for management and therapy." | ( Foulks, GN, 2008) |
| "Many patients with dry eyes remain untreated due to improper diagnoses." | ( Ajaiyeoba, A; Ajayi, BG; Akang, EE; Baiyeroju, AM; Bekibele, CO, 2010) |
| "Current dry eye treatment includes delivering comfort agents to the eye via drops, but low bioavailability and multiple administration continues to be a barrier to effective treatment." | ( Ali, M; Byrne, ME, 2009) |
| "The botulinum toxin B-induced dry eye mouse model is potentially useful in evaluating new dry eye treatment." | ( Chae, JJ; Chuck, RS; Hongyok, T; Li, L; Na, D; Shin, YJ, 2009) |
| "Twenty-one patients diagnosed with dry eye syndrome secondary to vernal keratoconjunctivitis (7 cases), atopic keratoconjunctivitis (8 cases), and ocular rosacea (6 cases) were treated twice a day with a 0." | ( Denoyer, A; Nochez, Y; Pisella, PJ, 2009) |
| "A total of 30 Taiwanese patients with dry eye syndrome were included and randomly assigned to the 2 treatment groups: the mean (SD) age was 40." | ( Chou, HC; Ho, JD; Huang, MC; Lin, SY; Wang, IJ; Wang, TJ, 2010) |
| "To assess the prognosis of dry eye in patients treated with cyclosporine 0." | ( Rao, SN, 2010) |
| "The efficacy of hormone therapy (HT) on dry eye syndrome remains debatable." | ( Kaewrudee, S; Luanratanakorn, P; Piwkumsribonruang, N; Somboonporn, W; Soontrapa, S; Tharnprisan, P, 2010) |
| "Treatment of patients with dry eye for 6 months with topical cyclosporine A resulted in an increase in Schirmer test results, an increase in BUT scores, and an improvement in cytological grade of the disease." | ( Gülbahçe, R; Hoşal, BM; Sahli, E; Ustün, H; Zilelioğlu, G, 2010) |
| "Signs and symptoms of dry eye were compared along 28 days of treatment." | ( Baumane, K; Laganovska, G; Pirondini, C; Radecka, L; Ratiglia, R; Villani, E; Viola, F, 2011) |
| "Symptoms and signs of dry eye showed significant differences between the 2 groups after 2 and 4 weeks of treatment." | ( Baumane, K; Laganovska, G; Pirondini, C; Radecka, L; Ratiglia, R; Villani, E; Viola, F, 2011) |
| "As the signs and symptoms of dry eye disease worsened, the patient initiated therapy with once-daily hydroxypropyl cellulose ophthalmic inserts." | ( Wander, AH, 2011) |
| "To develop a dry eye model of mouse induced by topical administration of benzalkonium chloride (BAC) and investigate the possible mechanisms." | ( Bai, L; He, H; Lin, Z; Liu, X; Liu, Z; Wang, Y; Zhou, T, 2011) |
| "Use of long-term diclofenac sodium for dry eye after radiotherapy was possibly responsible for the spontaneous corneal perforation in our patient." | ( Demirel, S; Sarac, O, 2012) |
| "Eighteen patients with dry eye disease requiring medical therapy and/or punctal occlusion were recruited for this prospective, nonrandomized, observational case series." | ( Huang, D; Li, Y; Nguyen, P; Pappuru, RR; Ramos, S; Sadda, SR; Yiu, SC, 2012) |
| "To determine symptoms improvement in dry eye patients with short-term autologous serum (AS) eyedrops treatment using the standardized Ocular Surface Disease Index (OSDI) survey." | ( Alfaro, J; Hernandez, H; Huidobro, A; Urzua, CA; Vasquez, DH, 2012) |
| "Various types of dry eye treatment drugs have been developed." | ( Imanaka, T; Nakamura, M; Sakamoto, A, 2012) |
| "Diquafosol was effective in the treatment of dry eye disease at an optimal dose of 3% six times a day." | ( Imanaka, T; Nakamura, M; Sakamoto, A, 2012) |
| "Acupuncture treatment for dry eye may meet this requirement." | ( Miao, WH; Shi, JL, 2012) |
| "Nineteen control and 18 dry eye subjects used each product for 2 weeks, three times per day, in a random order, with a minimum 1-week washout between treatment periods." | ( Madden, LC; Simmons, PA; Tomlinson, A, 2013) |
| "Secondary subjective end points were dry eye-related ocular symptoms (foreign body sensation, dryness, photophobia, eye pain, and blurred vision) score and the patients' overall treatment impression score." | ( Awamura, S; Kinoshita, S; Nakamichi, N; Oshiden, K; Suzuki, H; Yokoi, N, 2013) |
| "Sixty-four patients with dry eye symptoms between the ages of 45 and 90 years were randomized into 2 groups: 33 persons in the treatment group and 31 persons in the placebo group." | ( Eftekhari, MH; Ghassemi-Broumand, M; Hashemi, H; Kangari, H; Khabazkhoob, M; Salamzadeh, J; Sardari, S, 2013) |
| "We assessed 12 subjective dry eye symptoms, corneal and conjunctival staining with fluorescein, tear film break-up time (BUT), lower tear meniscus height measured with anterior-segment optical coherence tomography, Schirmer's testing, and adverse reactions at baseline and 1, 3, and 6 months after the start of treatment." | ( Ikeda, C; Koh, S; Maeda, N; Nishida, K; Takai, Y; Watanabe, H, 2013) |
| "Treatment of mouse dry eye with osmoprotectants significantly reduced corneal staining on day 35 compared with day 21 (schedule 2)." | ( Chen, Q; Chen, W; Garrett, Q; Hou, C; Li, J; Wang, Y; Zhang, X, 2013) |
| "The application of AS in dry eye treatment has gained popularity as a second-line therapy in the treatment of dry eye." | ( Akpek, EK; Angelina, A; Heflin, T; Marrone, M; Pan, Q; Stark, WJ; Tang, L; Zambrano, A, 2013) |
| "In experimental dry eye disease, tofacitinib treatment twice per day significantly decreased corneal fluorescein staining on days 12 and 15." | ( Chauhan, SK; Dana, R; Hua, J; Huang, JF; Kodati, S; Sadrai, Z; Stevenson, W, 2014) |
| "The severity level of dry eye patients was classified based on the Korean guidelines for dry eye treatment." | ( Choi, C; Chung, E; Hyon, JY; Kim, HM; Lee, D; Lee, J; Song, JS, 2014) |
| "Similar dry eye signs or symptoms improved after 3 months of treatment reducing dryness, hyperemia, follicular hyperplasia, and foreign body sensation." | ( Figus, M; Fogagnolo, P; Frezzotti, P; Iester, M; Motolese, I; Perdicchi, A; Telani, S, 2014) |
| "In moderate to severe dry eye in Hansen's disease, serum therapy in comparison with AT drops, improves clinical parameters and causes betterment in tear protein profile." | ( Datta, H; Mukhopadhyay, S; Sen, S, 2015) |
| "Millions of Americans suffer from dry eye disease, and there are few effective therapies capable of treating these patients." | ( Aluri, SR; Gustafson, JA; Hamm-Alvarez, SF; Hsueh, PY; Jashnani, A; Laurie, GW; MacKay, JA; McKown, RL; Wang, W; Yarber, F, 2015) |
| "To compare the responses to dry eye treatment of patients sorted by the degree of lower lid laxity." | ( Lee, NY; Lyu, B; Oh, SH; Yim, HB, 2016) |
| "Nine patients with severe dry eye were treated with either RGN-259 (0." | ( Dunn, SP; Kim, C; Sosne, G, 2015) |
| "By considering two dry eye case scenarios, this review evaluates the currently available evidence relating to DED therapy to describe a pragmatic clinical approach to best-practice management of dry eye patients." | ( Downie, LE; Keller, PR, 2015) |
| "Current dry eye treatment includes delivering comfort enhancing agents to the eye via eye drops, but low residence time of eye drops leads to low bioavailability." | ( Maulvi, FA; Shah, DO; Soni, TG, 2015) |
| "Because of the high incidence of dry eye among postmenopausal women that may be related to the hormonal treatment, we propose that a multidisciplinary approach should be considered between gynecologists and ophthalmologists in management of this disorder." | ( Mircheff, AK; Sriprasert, I; Stanczyk, FZ; Warren, DW, 2016) |
| "This retrospective study included 38 dry eye patients (11 with SS and 27 with non-SS) who were treated with 3% diquafosol due to lack of response to artificial tear treatment for more than 3 months." | ( Hyon, JY; Jeon, HS, 2016) |
| "Eye diseases, such as dry eye syndrome, are commonly treated with eye drop formulations." | ( Ahmad, A; Boyd, S; Chang, CN; Dozois, MD; Gu, FX; Hileeto, D; Jones, LW; Liang, H; Liu, S; Ng, DL; Reyad, MM, 2016) |
| "Investigating normal and dry eye conditions through tear analysis may clarify the pathophysiology of dry eye conditions and support the efficacy of treatments." | ( Akune, Y; Shigeyasu, C; Yamada, M, 2016) |
| "At day three, following dry eye confirmation by corneal fluorescein staining (CFS, score 0-15) and phenol red thread (PRT) lacrimation test, the mice (n = 10/gp) were either treated 3 times a day in both eyes with drug-free cationic emulsion, a 0." | ( Antonelli, S; Barabino, S; Cimbolini, N; Daull, P; Feraille, L; Garrigue, JS; Mauro, V, 2016) |
| "To investigate dry eye development in the patients receiving systemic retinoic acid therapy and to compare effectiveness of Autologous Serum (AS) and preservative free artificial tear (PFAT) in the patients with dry eye disease." | ( Gökler, E; Koç, Ç; Küçük, E; Yılmaz, U, 2017) |
| "Patients detected as having dry eye during systemic isotretinoin treatment were included to our study." | ( Gökler, E; Koç, Ç; Küçük, E; Yılmaz, U, 2017) |
| "Successful treatment of dry eye should be aimed to restore the homeostasis of the ocular surface microenvironment." | ( Bu, J; He, X; Jia, C; Li, W; Liu, Z; M, VJ; Ou, S; Qu, Y; Wang, J; Wu, H; Zhang, X, 2017) |
| "In a rabbit dry eye model, corneal epithelial defects was ameliorated by treatment with single-dose administration of EGCG-containing GN." | ( Lai, JY; Luo, LJ, 2017) |
| "To compare the response of dry eye disease (DED) to treatment with topical steroid in patients with and without graft-vs-host disease (GVHD)." | ( Dana, R; Dohlman, T; Kheirkhah, A; Saboo, U; Yin, J, 2018) |
| "These drugs treat keratoconus and dry eye syndrome, respectively." | ( Aserin, A; Garti, N; Garti-Levy, S; Lidich, N, 2019) |
| "To determine the mucinogenic effect of dry eye (DE) treatment drugs currently in use, we compared the levels of mucin production and inflammatory cytokine expression on the ocular surfaces using a DE-induced mice model." | ( Ji, YW; Kang, HG; Kim, HC; Lee, HK; Moon, I; Noh, H; Song, JS; Yeo, A, 2018) |
| "Patients with severe dry eye disease (DED) often have limited treatment options with standard non-surgical management focused on the use of artificial tears for lubrication and anti-inflammatory drugs." | ( Ahmad, S; Balal, S; Barton, G; Bourne, RRA; Cook, E; Harrison, M; Hassan, A; Hayden, K; Pappas, Y; Pardhan, S; Sharma, A; Sharma, B; Udoh, A; Wasil, M, 2018) |
| "To do this, dry eye and corneal epithelial injuries were induced in rabbits by topical administration of atropine sulfate and NaOH." | ( Bermudez, MA; Eiro, N; Gonzalez, F; Martinez-Ordoñez, A; Perez-Fernandez, R; Saa, J; Sendon-Lago, J; Seoane, S; Vizoso, FJ, 2019) |
| "Following dry eye confirmation by corneal fluorescein staining (CFS), the mice were treated three times a day with: 0." | ( Barabino, S; Baudouin, C; Daull, P; Docquier, M; Feraille, L; Garrigue, JS; Kessal, K; Parsadaniantz, SM, 2019) |
| "Twenty patients with depression and dry eye disease (DED) were randomly picked to receive SSRI treatment, whereas another 20 patients received placebo treatment." | ( Gong, L; Yin, Y; Yue, L; Zhang, X, 2019) |
| "One of the key challenges in dry eye syndrome therapy is to find a suitable carrier for immunosuppressant drug - cyclosporine A (CsA) - delivery to the eye." | ( Chachaj-Brekiesz, A; Dynarowicz-Latka, P; Kobierski, J; Lipiec, E; Wnętrzak, A, 2019) |
| "In the treatment of dry eye disease, HA provides water retention and lubricant properties that challenge current treatment." | ( Huynh, A; Priefer, R, 2020) |
| "Addressing these will improve dry eye practice and treatment outcomes in the country." | ( Cox, SM; Nichols, KK; Osei, KA, 2020) |
| "The treatment of dry eye in these patients is difficult to manage, with topical immunomodulators such as cyclosporine A as a good alternative when lubricants are insufficient." | ( Botella García, J; de la Paz, MF; Lázaro-Rodríguez, V, 2022) |
| "Allergic conjunctivitis and dry eye syndrome are common ocular surface diseases that have been treated with traditional pharmacological measures, e." | ( Bielory, L; Tabliago, NRA, 2020) |
| "A literature review of published dry eye clinical trials was performed to identify the pivotal clinical trials of DED medications and to compare treatment effect and further understand the impact of the vehicle on clinical trial outcomes." | ( Evans, DG; Karpecki, PM; Nichols, KK, 2021) |
| "In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 μM) or solvent four times a day." | ( Cao, W; Chen, Z; Chu, L; Ma, S, 2021) |
| "The treatment of dry eye disease must be individualized, dynamic and optimized for each stage of the disease." | ( Zemanová, M, 2021) |
| "The present rabbit dry eye model study demonstrated potentials of topically administered 0." | ( Wang, M; Wang, Z; Yu, L; Zhang, S, 2022) |
| "The effectiveness of the OAS dry eye model in NZW rabbits as reported in previous studies was confirmed, provided that the application of the drug is maintained throughout the intervention; it is not a viable model after OAS administration is suspended." | ( Baiza-Durán, L; Correa-Gallegos, EY; Medina-Espinoza, JM; Muñoz-Villegas, P; Navarro-Sanchez, AA; Olvera-Montaño, O; Sánchez-Ríos, A, 2022) |
| "Early treatments of dry eye and collaborations among multidisciplinary physicians are necessary in patients with AIBD." | ( Feng, J; He, Y; Kang, H; Liu, Y; Peng, Y; Ren, Y; Shi, W; Tan, Y; Wu, M; Wu, R; Zhang, G, 2022) |
| "Medical records of 188 patients with dry eye after phacoemulsification, treated in our hospital from August 2020 to August 2021, were included and divided into groups based on the type of dry eye treatment." | ( Guan, Y; Lu, H; Nan, N; Su, Y; Yuan, Y, 2022) |
| "Medical records of 188 patients with dry eye after phacoemulsification, treated in our hospital from August 2020 to August 2021, were included and divided into groups based on the type of dry eye treatment." | ( Guan, Y; Lu, H; Nan, N; Su, Y; Yuan, Y, 2022) |
| "There is a clinical necessity for dry eye disease treatments that perform across a broad range of presenting patient severities." | ( Blemker, G; Gibson, A; Hemphill, M; Hendrix, LH; Karpecki, PM; Macsai, M; O'Dell, LE; Raizman, MB; Sheppard, JD; Whitley, WO, 2023) |
| "To study the incidence of dry eye disease (DED) in head and neck cancer (HNC) patients undergoing external beam radiotherapy (EBRT), to find a correlation between tumor location and total radiation dose with DED, and to report various radiotherapy (RT) induced acute toxic effects on ocular and adnexal structures." | ( Jain, P; Soni, M; Walia, S, 2023) |
| "The treatment of dry eye mainly includes instillation of cyclosporine A (CsA) nanoemulsion or the use of punctal plugs." | ( Bai, S; Cao, Z; Chen, Y; Gui, S; He, N; Liu, Y; Shan, S; Wu, J; Zheng, Z, 2023) |
| "To identify specific dry eye disease (DED) tear biomarker(s) using tear proteomic analysis, clinical parameters, and their correlations before and after DED treatment." | ( An, WJ; Choi, CY; Chung, TY; Jeon, S; Jeong, SJ; Jung, GT; Kim, HS; Kim, KP; Kim, M; Kim, TI; Lee, HK; Lee, HS; Song, JS, 2023) |
| "affine, as a novel treatment for dry eye disease (DED)." | ( Ahn, KS; Chung, JH; Jang, HJ; Ko, JH; Oh, JH; Oh, JY; Oh, SR; Ryu, JS; Yoon, CH, 2023) |
| "A mouse model of dry eye was established by administering with BAC to BALB/c mice, and the expression of TNF-α, IL-1β, IL-6, IL-8, cyclooxygenase 2 (COX2), interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6) in the corneas of dry eye model mice was significantly increased; this was accompanied by the upregulation of miR-146a and activation of the NF-κB pathway." | ( Chen, X; Gao, J; Han, R; Hao, P; Jiang, L; Jiang, Z; Li, X; Wang, L; Wang, T; Wang, Y; Zhu, L, 2023) |
| "A total of 126 patients (126 eyes) with dry eye syndrome after cataract surgery were treated between January 2021 and October 2022." | ( Fu, J; Jia, Q; Zhao, X, 2023) |
| "Differentiating dry eye disease (DED) from allergic or viral conjunctivitis rapidly and accurately is important to ensure prompt diagnosis and treatment." | ( Tang, H; Yan, P; Zhang, J; Zhang, Y, 2023) |
| "Although dry eye disease (DED) is one of the most common ocular surface diseases worldwide, its pathogenesis is incompletely understood, and treatment options are limited." | ( De Goüyon Matignon de Pontourade, CMF; Keller, I; Lincke, JB; Schlegel, I; Zinkernagel, MS; Zysset-Burri, DC, 2023) |